fbpx

Genome Sequencing - Article & Videos

What is Happening to Pacific Biosciences Stock?
April 17. 2024. 6 mins read

Someone once said that bankruptcy happens very slowly, then all of a sudden. That’s about...

10X Genomics Continues Expanding Platform Menu
February 20. 2024. 7 mins read

When not busy trying to resurrect the wooly mammoth, geneticist George Church spends his time...

Can Oxford Nanopore Continue to Grow Revenues?
January 29. 2024. 7 mins read

Last year, we asked a big question in one of our year-end articles: Is It...

10x Genomics Stock: The Illumina of Single-Cell Analysis?
June 19. 2023. 9 mins read

The United States is famously the most litigious society in the world. One statistic we’ve...

Should You Buy Pacific Biosciences Stock Now?
May 27. 2023. 8 mins read

Earlier this month we dissected the ongoing battle between investor activist Carl Icahn and the...

Checking in With Oxford Nanopore Stock
March 27. 2023. 7 mins read

Regular readers know that we don’t get distracted or unnerved by dropping stock prices. It’s...

Illumina Stock Falls on GRAIL Acquisition Fail
October 17. 2022. 6 mins read

Unless you can watch your stock holding decline by 50% without becoming panic-stricken, you should...

10x Genomics Stock Plummets: Why We’re Not Worried
May 31. 2022. 6 mins read

“Every cell in your body has the same DNA. Except it doesn’t.” That was the...

Bionano Genomics Stock: What Exactly Do They Do?
April 13. 2022. 7 mins read

Technological innovation comes and goes constantly. Retail investors should only concern themselves with technology that...

Pacific Biosciences Stock Falls While Revenue Rises
April 6. 2022. 4 mins read

One of Warren Buffett’s many notable quotes is that “if you’ve been playing poker for...

An Update on Long-Read Sequencing Stocks
March 28. 2022. 8 mins read

Spending an afternoon on the Oxford campus is a special experience that opens your eyes...

What’s Up With Illumina’s Acquisition of GRAIL?
September 28. 2021. 7 mins read

If you want to land a job at a top investment bank, there’s an expectation...